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The prolongation of the QT interval represents the main feature of the long QT syndrome
(LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of
the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects due
to an increase in the late component of the sodium current (INaL). The two sodium blockers
flecainide and ranolazine are equally recommended by the current 2015 ESC guidelines to
treat patients with LQTS type 3 and persistently prolonged QT intervals. However,
awareness of pro-arrhythmic effects of flecainide in LQTS type 3 patients arose upon
the study of the SCN5A E1784K mutation. Regarding SCN5A V411M individuals,
flecainide showed good results albeit in a reduced number of patients and no
evidence supporting the use of ranolazine has ever been released. Therefore, we
ought to compare the effect of ranolazine and flecainide in a SCN5A V411M model
using an in-silico modeling and simulation approach. We collected clinical data of four
patients. Then, we fitted four Markovian models of the human sodium current (INa) to
experimental and clinical data. Two of them correspond to the wild type and the
heterozygous SCN5A V411M scenarios, and the other two mimic the effects of
flecainide and ranolazine on INa. Next, we inserted them into three isolated cell action
potential (AP) models for endocardial, midmyocardial and epicardial cells and in a one-
dimensional tissue model. The SCN5A V411M mutation produced a 15.9% APD90
prolongation in the isolated endocardial cell model, which corresponded to a 14.3% of
the QT interval prolongation in a one-dimensional strand model, in keeping with clinical
observations. Although with different underlying mechanisms, flecainide and ranolazine
partially countered this prolongation at the isolated endocardial model by reducing the
APD90 by 8.7 and 4.3%, and the QT interval by 7.2 and 3.2%, respectively. While
flecainide specifically targeted the mutation-induced increase in peak INaL, ranolazine
reduced it during the entire AP. Our simulations also suggest that ranolazine could prevent
early afterdepolarizations triggered by the SCN5A V411Mmutation during bradycardia, as
flecainide. We conclude that ranolazine could be used to treat SCN5A V411M patients,
specifically when flecainide is contraindicated.
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INTRODUCTION
Mutations in genes encoding ion channels are regarded as the
molecular basis of the congenital Long QT Syndrome (LQTS).
Abnormal proteins expressed at the heart result in disrupted
electrical activity that pose the patients at an increased risk of
lethal arrhythmias such as Torsade-de-pointes. Seventeen types of
congenital LQTS with autosomal dominant inheritance pattern
and 2 types of autosomal recessive LQTS have been described so
far. Five of them affect the activity of the sodium current (INa)
(Bohnen et al., 2017) and also account for 5–10% of the cases
(Ackerman et al., 2011). Mutations in the SCN5A gene (LQTS
type 3), which encodes the main protein of INa, and mutations in
the genes encoding its regulatory proteins (LQTS 4, LQTS 9, LQTS
10 and LQTS 12) can in fact cause LQTS as long as the mutations
result in a gain-of-function of the late sodium current. Current
clinical guidelines and independent research papers recommend
beta-blockers and may consider the addition of several drugs such
as ranolazine, mexiletine, flecainide or lidocaine when treating
LQTS type 3 patients with QTc over 500 ms (Priori et al., 2015;
Bengel et al., 2017; Bohnen et al., 2017). However, some concern
was raised when the SCN5A overlap syndrome was identified in
patients exhibiting not only a LQTS type 3 phenotype but also
Brugada syndrome and conduction defect features. In them, high
temperatures and/or the administration of flecainide could
unmask the other phenotypes and trigger life-threatening
arrhythmias (Makita et al., 2008; Abdelsayed et al., 2015). Basic
research on these drugs has revealed that drug-channel interaction
is complex and not just limited to a specific blockade of part of
INa, the fast (INaf) or the late (INaL) components.
Patients with the V411M mutation in the SCN5A gene present
congenital LQTS type 3 with symptoms very early in life and, if left
untreated, can lead to severe arrhythmia (Carrasco et al., 2012; Blich
et al., 2019). The clinical beneficial effects of flecainide on
ventricular arrhythmia management and on QTc measurements
in patients with LQTS type 3, specifically those harboring the
V411M mutation, is consistent with its blocking effect on INa
(Carrasco et al., 2012; Blich et al., 2019). It has been hypothesized
that these positive outcomes rely on a high affinity binding and
subsequent blocking of the open state of the sodium channel.
Flecainide is a class IC antiarrhythmic drug because of its ability
to block sodium channels and it is effective both for cardioversion as
well as sinus rhythm maintenance in atrial fibrillation (Aliot et al.,
2011). It has been used in the clinical practice for a long time—in
Europe since 1982—while showing a good safety profile if correctly
monitored (Aliot et al., 2011). By contrast, lidocaine showed no
effect on a patient with the V411M heterozygous mutation (Horne
et al., 2011). Ranolazine is a relatively new class IB antiarrhythmic
drug with selective INaL block that has shown effectiveness in the
treatment of angina pectoris and in patients with LQTS caused by
the D1790G mutation (Chorin et al., 2016) but, to the best of our
knowledge, it has not been tested in patients with V411Mmutation.
Mathematical models are innovative tools that can provide useful
insights into the mechanisms that drive the electrical activity of the
heart. Markov models of the ion channels are specially indicated to
study ion channels gating and their interaction with drugs. They
describe the different states that channels can occupy, which
correspond to different channel conformations. Transitions between
these states are described through detailed descriptions of time and
voltage-dependent transition velocities (Rudy and Silva, 2006). They
have already beenused tomodel and test the effects of drugs inmultiple
scenarios, including mutated cardiomyocytes. For example, drugs
affecting the rapid component of the delayed rectifier potassium
current (IKr) have been modeled to enable a better understanding
of their interactions (Romero et al., 2015; Li et al., 2017; Yang et al.,
2020), and have been successfully validated for proarrhythmia
assessment (Chang et al., 2017) at the core of the in-silico section
of the Comprehensive In-vitro Proarrhythmia Assay initiative (CiPA).
Similarly, Moreno et al. (Moreno et al., 2013) modeled both INa and
SCN5A ΔKPQ, a LQTS type 3-inducing mutation that prolongs the
action potential duration (APD) of cardiac cells by increasing the
sustained component of INa, creating the perfect conditions for early
afterdepolarizations (EADs) occurrence. Moreover, these authors
proposed mathematical formulations for flecainide, ranolazine and
lidocaine and tested their effects in catecholaminergic polymorphic
ventricular tachycardia serving as a proof-of-concept of a multi-drug
treatment (Yang et al., 2016a).
It is well known that INaL is a key component in the regulation of the
APD (Saint, 2009) especially in conditions of specific heart diseases,
such as heart failure and angina (Moreno and Clancy, 2012; Trenor
et al., 2012; Makielski, 2016; Chadda et al., 2017). However, this
component of the sodium current is not easy to characterize.
Recently, new experimental methods to characterize INaL have been
proposed. Indeed, to better capture the dynamics of INaL during the AP
and its role in arrhythmogenesis, works byHorvath et al. (2013), Hegyi
et al. (2018) used self-AP clamp techniques to characterize the current’s
time course instead of using the traditional single rectangular pulse. In
addition, Li et al. (2017) found that INaL was one of the three main
currents whose block should be taken into account to improve drug
proarrhythmicity prediction when simulating the electrophysiological
effects of drug-channel interactions.
Herein, we attempt to shed light into the mechanisms behind the
heterozygous SCN5A V411M mutation phenotype and to study the
potential of ranolazine to reduce its abnormal behavior as an
alternative to flecainide by using computer simulations. Moreover,
we gained insights into themechanisms of these two drugs tomitigate
themutation phenotype. To do so, first, we improved the well-known
(Moreno et al., 2013) INa model by adjusting it to new INaL data and
generated a new model for the V411M mutation. Then, we refitted
themodels for both drugs, flecainide and ranolazine, while improving
the former with new tests, to evaluate their potential therapeutic
effects at several pacing rates both on isolated cell and tissue model
conditions. Finally, we explored the compounds’ potential to prevent
arrhythmia triggers during bradycardia. This study represents one
step forward to the implementation of computational tools fulfill the
promise of personalized and precision medicine.
MATERIALS AND METHODS
Markovian Sodium Channel Model
We optimized the wild-type sodium channel model from
(Moreno et al., 2013), as well as the updated version of
flecainide including bursting states (Yang et al., 2016b) and
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ranolazine (Moreno et al., 2013) to reproduce additional
experimental data (Penniman et al., 2010; Horvath et al.,
2013). These are part of a framework that focuses on
facilitating the process of combining experimental data into
functional ion channel models (Moreno et al., 2016). Their
versatility, combined with their highly detailed formulation
based on works that span more than 20 years of research,
represents a suitable substrate for our objectives. We generated
a V411Mmutated model that can be set in homo or heterozygous
configuration from the updated wild-type version. Simulation of
the heterozygous V411M mutation was modeled by combining
50% wild type and 50% mutant currents, as in Moreno et al.
(2013). The homozygous model was used in in-silico patch-clamp
experiments while the heterozygous model was used to simulate
action potentials (APs). All INa models were constrained by
microscopic reversibility (Colquhoun et al., 2004).
Isolated Cellular Action Potential Models
We used the Grandi et al. (2010) modified with Soltis and
Saucerman (2010) by Moreno et al. (2013) epicardial model as
a starting point. Then, we modified the current conductances
(O’Hara et al., 2011) to create endocardial and midmyocardial
versions, which were fitted to their respective APD at 90%
repolarization (APD90) restitution curves (see Supplementary
Figure S1). We gathered the specific changes in conductances
between cell types in Supplementary Table S1. In order to reduce
computational demand of our model fits, we first used the APD of
the endocardial cellular model as a surrogate of the QT interval, as
in a previous work of our group (Romero et al., 2018) we found
that risk prediction based on 10% of the human endocardial
APD90 and QT prolongations gave very similar results.
Transmural Wedge Model
The ventricular transmural wedge model consisted of 165 cells
connected in a row, split in three zones of 60, 45 and 60
endocardial, midmyocardial and epicardial cells, respectively.
Stimulation was applied to the first endocardial cell and
propagation through the strand was simulated using the
following nonlinear reaction diffusion equation:
Cm · zvm(x, t)
zt








where Cm is the membrane capacitance, “a” stands for the radius
of the fiber, “ΣIion” represents the sum of all the ionic currents
flowing through the cellular membrane, and “Ri” is the
intracellular resistivity.
The inclusion of a virtual electrode 2 cm away from the
epicardial end enabled the calculation of the pseudo-
electrocardiogram (ECG) of the strand, although the first and
last 15 cells were not taken into account for this purpose to
prevent boundary effects.
Simulation Protocols
Unless specified, we paced the models at a rate of 1 Hz, a frequency
that is widely used in human cardiomyocyte simulation (Elkins
et al., 2013; Crumb et al., 2016; Lancaster and Sobie, 2016) in the
absence of β-adrenergic stimulation. These conditions would be
equivalent to the exposure to a β-blocker drug. The single cellular
model was stimulated with square pulse of −9.5 pA/pF and 5m
duration. The model was simulated with a custom C++ script. State
occupancy probabilities in the INaMarkovmodel were calculated by
an implicit Trapezoidal numerical method. The numerical method
used to update the voltage was forward Euler.
Patch clamp simulations of the INa channel were simulated
using a customMatlab (The Mathworks, inc.) script including an
ordinary differential equation solver with variable time step.
The ventricular transmural wedge model was stimulated with
a −400 pA/pF square pulse of 0.5 m applied to the first
endocardial cell. The numerical method used to simulate the
model was Forward Euler with a fixed time step of 0.005 m and it
was run using a customized C++ code.
Both ranolazine and flecainide showed evidence of blocking
the rapid component of the delayed rectifier potassium current
(IKr). We simulated it by using the Hill formalism, consisting of
the following equation:
fo  1
1 + ( CIC50)H
Where fo is remaining conductance of the channel at a
concentration C of a drug exhibiting a half-maximal block
concentration for the channel of IC50, and modulated by H,
the Hill coefficient, which was set to 1 as in our previous work
(Romero et al., 2018).
In order to reduce computational cost, simulation of the APD90
restitution curve in wild type, the prolongation in V411Mmutation
and the prolongation in flecainide were performed using the
following procedure. We first paced the original Moreno et al.
(2013) INa model (Moreno et al., 2013) for 300 pulses for each case
and the state variables were saved. Then, they were used as initial
conditions in the optimization procedure and a train of 40 pulses
was applied to the isolated endocardial cell models for each iteration.
Details of the methods including patch clamp, simulation and
optimization protocols are available in the Supplementary
Material of this work.
Clinical Characterization
Two dedicated clinics with expertise in channelopathies enrolled
LQTS patients heterozygous for the SCN5A V411M mutation.
Exclusion criteria was “not willing to take part in the study.” The
study protocol was approved by the local ethics committee. The QT
interval was manually measured with the tangent method (Postema
et al., 2008) in at least three consecutive complexes from lead II,
unless the quality of the ECG or the presence of pronounced sinus
arrhythmiamade it reasonable to reduce the number of complexes to
two or choose nonconsecutive beats to gain accuracy, never looking
for the longest or shortest QT intervals. The freely accessible online
probability calculator for LQTS1 was used to obtain the QT interval
value with Bazzet correction (QTc) and a mean value was calculated
from resting 12-lead ECGs on beta-blocker treatment and, if
available, also naïve. Notably, the website provides the Gaussian
1www.QTcalculator.org[accessed 2019]
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percentiles of the QTc interval in controls of similar sex and age,
allowing us to identify the specific QTc value below which 90%
of the observations in controls (90th percentile) can be found.
Being very conservative, we took that value as the reference in
general population to calculate the magnitude of the
prolongation caused by the SCN5A V411M mutation in each
patient and a mean value for that effect (to that end, only naïve
ECG were taken into consideration).
RESULTS
QTc Measurements in Patients
Figure 1 shows a lead II from the ECGs obtained in the four patients
depicting theQTc value and the estimated probability of finding such
a value among controls and LQTS patients. As observed, naïve QTc
intervals were significantly prolonged and well above the well-known
cutoff of 500ms and the two youngest patients additionally exhibited
atrioventricular block 2:1. The use of beta-blockers could only mildly
ameliorate QTc values. In order to estimate the QTc
prolongation attributable to the SCN5A V411M mutation, we
considered the QTc of patients with beta-blockers as our
reference since our models were ran without accounting for
beta stimulation. Two QTc values were obtained from each of
four patients, as described in Table 1. The QTc increments
ranged from 8.9 to 28.1% and the average was 19.9%.
Models
To evaluate the usefulness of either flecainide or ranolazine as
treatments for the LQTS type 3 syndrome caused by the SCN5A
V411M mutation, we selected the Grandi-Bers with Soltis-
Saucerman human epicardial cell model (GBers-SS) modified
by Moreno et al. (2013) as a starting point because it includes
their Markovian sodium channel formulation.
We modified several GBers-SS ionic current conductances
following the same procedure as in O’Hara et al. (2011) to
FIGURE 1 | ECG recordings from our patients. Lead II recordings from the ECGs of four patients with the heterozygous SCN5A V411M mutation, along with
information about their measured QTc values in naïve (without treatment) and under β-blocker treatment (nadolol or propranolol). A “P” precedes the percentile to which
QTc values belong.
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generate endocardial and mid-myocardial versions from the
epicardial one. Then, we fitted the wild type sodium current
model using the endocardial version of the human ventricular
action potential. Next, we tuned it to mimic the effects of the
mutation, and finally, we adapted the flecainide model to
additional experimental data and updated the ranolazine
model for the new wild type model.
Wild Type Sodium Current Optimization
Results and Analysis
The sodium channel formulation proposed by Moreno et al.
(2013) includes 12 states describing its precise conformations
which include three closed, four inactive, four bursting and one
open state. Transition rates between states are voltage dependent,
adding to the complexity of the model and contributing to its
ability to fit given dynamics. The bursting state mode (four states
indicated with a B) represents the portion of the channels that are
unable to correctly inactivate, contributing to the current’s late
component. This feature, which was added later during the model
development, shows that new features can be added in the future,
if necessary, to account for new discoveries. We depicted the
precise states and state transition velocities of the sodium current
model in Figure 2.
Making use of the inter-experimental compatibility of Moreno
and coworkers framework, we created a batch of tests designed to
TABLE 1 | Patients information.
Patient Gender Age (years) β-blocking Drug QTc (ms) QTc leaving 90% of control QTc below (ms) QTc increment (%)
1 Male 1 Nadolol 542 434 24.9
(7 months) 516 434 18.9
2 Female 29 Nadolol 503 437 15.1
498 437 14.0
3 Female 11 Nadolol 555 434 27.9
528 434 21.7
4 Female 2 Propranolol 471 434 8.5
556 434 28.1
Average 19.9
This table contains anonymized relevant data of our four patients (from 1 to 4), namely, from left to right, their assigned code, gender, age (in years), the name of the administered β-blocking
drug, registered QTc interval values (in ms), reference QTc values (in ms) and calculated QTc increment (in %). The last row shows the average QTc increment.
FIGURE 2 | Diagram of the sodium channel Markovian model. The channel can be in closed (C), inactivated (I) or open (O) states as indicated by their name. The
model has fast (IF, IC2, IC3) and slow (IS) inactivation dynamics, as well as a bursting mode of operation (B). Flecainide (but not ranolazine) trapping dynamics are
represented by the trapped state (IT). Transitions between states are indicated with solid arrows, together with their respective transition rates. Drug-free states are
depicted in black (wild type or mutated), charged drug-bound channels in red and neutral drug-bound states in blue. Binding (on) and unbinding (off) rates (k)
determine the transitions between models, shown with dotted arrows. Color-coded zones indicate channel states that are connected to each other, but their arrows
have been omitted for clarity. Yellow zones highlight the bursting states where the charged drug the binds and unbinds, the transition rates being kbc_on and kc_on for
the binding and kbc_off and kc_off for the unbinding. Cyan zones highlight the inactive states where the neutral drug the binds and unbinds, the transition rates being
ki_on for the binding and ki_off for the unbinding.
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 5804815
Cano et al. Ranolazine in LQTS Type 3
TABLE 2 | Transition rates of the post-optimization wild type model.
States Transition rates
IC3 →IC2, C3→C2, BC3→BC2 α11  Tf × 8.5539/(6.59e-2×exp(−v/(17.0))+2.76e-1×exp(−v/(150)))
IC2→IF, C2→C1, BC2→BC1 α12  Tf × 8.5539/(6.59e-2×exp(−v/(15.0))+2.76e-1×exp(−v/(150)))
C1→O, BC1→BO α13  Tf × 8.5539/(6.59e-2×exp(−v/(12.0))+2.76e-1×exp(−v/(150)))
IC2→IC3, C2→C3, BC2→BC3 β11  Tf × 6.98e-2×exp(−v/20.3)
IF→IC2, C1→C2, BC1→BC2 β12  Tf × 3.04×exp(−(v-5)/20.3)
O→C1, BO→BC1 β13  Tf × 1.18×exp(−(v-10)/20.3)
IC3→C3, IC2→C2, IF→C1 α3  Tf × 8.06e-6×exp(−v/(8.43))
C3→IC3, C2→IC2, C1→IF β3  Tf × 6.45×exp((v)/(1.48e1))
O→IF α2  Tf × 3.54×exp(v/(3.81e1))
IF→O β2  (α13×α2×α3)/(β13×β3)
O→IS βx  2.30e-2×α3
IS→O αx  3.02e-2×α2
C3→BC3, C2→BC2, C1→BC1, O→BO µ1  1.70e-07
BC3→C3, BC2→C2, BC1→C1, BO→O µ2  5.66e-04
The first column indicates state transitions, while the second column specifies their corresponding transition rate names and equations. “Tf” is a temperature scaling factor calculated from
aQ10 of 3 as described in theSupplementaryMaterial of this work. Nomenclature for transition rates and affinities: charged drug (+), neutral drug (n), closed states (c), inactivated states
(i), bursting states (b), drug binding to the channel (on), drug unbinding from the channel (off).
FIGURE 3 |Optimization of the control model of the sodium current dynamics. Squares are references and lines are simulations (A–F). (A) Steady-state availability.
(B) Steady-state activation. (C) Recovery from inactivation. (D) Recovery from use-dependent block. (E) INaL current-voltage relationship. (F) APD90 Restitution curve of
an isolated endocardial cell. (G) time course of the sodium current’s slow component of an isolated endocardial cell. (H) time course of the membrane potential of and
isolated endocardial cell. Simulations using the original Moreno et al., 2013 model (yellow lines) and our new version (black lines) (G,H). Data are from Rivolta et al.
(2001) and Liu et al. (2002) (A–D), O’Hara et al. (2011) (E) and Maltsev et al. (1998) (F).
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re-fit their Markovian INa model (Moreno et al., 2013). These tests
considered its current-voltage relationship as (Moreno et al.,
2011), its time course, and the isolated endocardial APD90
restitution curve. In order to fit the time course of the sodium
current, we used the experimental data provided by Horvath et al.
(2013), who employed a self-AP clamp protocol for that purpose.
We started our fitting from Moreno et al. (2013) optimal
parameters, which reproduce very well the current-voltage
relationships. In order to overcome the local minimum
generated by this fact, we divided the wild type optimization
into two phases. Phase one simulated the endocardial APD90
restitution, current time course and maximum upstroke velocity
FIGURE 4 |Optimization of the SCN5A V411Mmutation model. Targets were represented as open squares, simulations using our SCN5A V411Mmutation model
as red lines and simulations using our wild type model as black lines. (A) Current-voltage relationship. (B) Steady state activation. (C) Steady state inactivation. (D)
Inactivation time constants. (E,F) Simulated isolated endocardial time course of the sodium current’s slow component and the action potential for wild type (black line)
and for heterozygous SCN5A V411M mutated (red line) cells. APD90 prolongation caused by the heterozygous mutation was a result of an increase in INaL as
observed in its time course in (E) and was calculated by comparing wild type and mutation action potential time courses in (F).
TABLE 3 | Transition rates of the post-optimization SCN5A V411M mutation model.
States Transition rates
IC3 →IC2, C3→C2, BC3→BC2 α11  Tf × 8.5539/(4.71e-2×exp(−v/(17.0))+2.52e-1×exp(−v/(150)))
IC2→IF, C2→C1, BC2→BC1 α12  Tf × 8.5539/(4.71e-2×exp(−v/(15.0))+2.52e-1×exp(−v/(150)))
C1→O, BC1→BO α13  Tf × 8.5539/(4.71e-2×exp(−v/(12.0))+2.52e-1×exp(−v/(150)))
IC2→IC3, C2→C3, BC2→BC3 β11  Tf × 5.65e-2×exp(−v/20.3)
IF→IC2, C1→C2, BC1→BC2 β12  Tf × 2.99×exp(−(v-5)/20.3)
O→C1, BO→BC1 β13  Tf × 2.59e-1×exp(−(v-10)/20.3)
IC3→C3, IC2→C2, IF→C1 α3  Tf × 1.42e-5×exp(−v/(9.48))
C3→IC3, C2→IC2, C1→IF β3  Tf × 6.96×exp((v)/(1.67e1))
O→IF α2  Tf × 7.01×exp(v/(3.16e1))
IF→O β2  (α13×α2×α3)/(β13×β3)
O→IS βx  2.08e-2×α3
IS→O αx  5.51e-2×α2
C3→BC3, C2→BC2, C1→BC1, O→BO µ1  1.70e-07
BC3→C3, BC2→C2, BC1→C1, BO→O µ2  5.66e-04
The first column indicates state transitions, while the second column specifies their corresponding transition rate names and equations. “Tf” is a temperature scaling factor calculated from
a Q10 of 3 as described in the Supplementary Material of this work.
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(max dV/dt). Phase two took into account the original patch
clamp protocols used by Moreno et al., 2011, which assess steady-
state availability, activation, recovery from inactivation, recovery
from use-dependent block and mean opening time dynamics.
The total charge carried by INaf (qNaf) was also controlled to
prevent the model from not depolarizing. Parameters and
equations of the final wild type model are shown in Table 2.
Figure 3 compares the simulation results of the wild type
sodium current model dynamics (black lines) to experimental data
(A-F, open squares). Figures 3A–D show the steady state
availability, steady state activation, recovery from inactivation
and recovery from use-dependent block, respectively. Figures
3E–H show the simulated INaL current-voltage relationship,
APD90 restitution curve of endocardial cell, the current’s time
course, and the membrane potential time course, respectively.
Although the new model shows some small differences with the
experimental data in the steady-state activation (Figures 3B) such
as a higher slope and a 10-mV left shift of the activation curve,
they are nonetheless within the range of commonly observed
activation dynamics from several sources (see Supplementary
Figure S3). Figures 3F shows that the simulated APD90 values at
300, 400, 500, 1,000, 1,500 and 2000 ms Basic Cycle Lengths
(BCLs), were respectively, 194.2, 209, 223.1, 268.6, 290.9 and
303.9 ms (open squares with SD bars are experimental
references, lines are simulations). The resulting inward dome
current was 0.291 pA/pF, consistent with Li et al. (2017), the
valley-to-dome current proportion was 48.0% and the half time
proportion was 59.3%, which are in concordance with Horvath
et al. (2013). A comparison between the sodium current time
courses obtained with the original INa model (gray line) and our
new version (black line) reveals a slight increase in plateau-phase
and a reduction in repolarization phase peak. The corresponding
action potential time courses were included in Figures 3H. The
new model shortened the APD as a consequence of the reduction
in late current during repolarization. The new max dV/dt (not
shown) was 289.9 V/s compared to 250 V/s (O’Hara et al., 2011).
Finally, the new late-to-fast current proportion was 0.08%, which
is close to 0.1%, calculated following the methods used by Clancy
et al. (2002). Overall, the post-optimization results show good
agreement between simulation and experiments.
SCN5A V411M Mutation Optimization
Results
To fit the LQTS type 3 SCN5A V411M mutation model we
constructed a batch of tests including specific patch clamp
protocols to characterize the channel’s activation, inactivation,
inactivation time constants, current-voltage relationship, and QT
prolongation. Parameters and equations of the final V411M
model are shown in Table 3. We performed a sensitivity
analysis of the V411M mutation’s parameters to get some
insights about how the differences between wild type and the
mutation parameters are related to the increment of INaL (see
Supplementary Figure S5A, Supplementary Table S2). The
results of the analysis suggest that the modifications that most
increased INaL were the decrease of β13 (deactivation, modulated
by p5), followed by an increase of α3 (recovery from inactivation,
modulated by p6 and p7).
Figures 4A–D compare the targets (open squares) obtained
from experimental results (Horne et al., 2011), the simulated
V411M mutation (red lines) and the simulated WT current-
voltage relationship, steady state activation, steady state
inactivation and inactivation time constants (black lines),
respectively. Protocols are described in Horne et al. (2011).
The resulting V411M mutation model fitted correctly the
target values, showing increased currents for test potentials
from −60 mV to almost 0 mV, doubling the wild-type current
for −40 mV to −30 mV test potentials, which are within the
repolarization phase of the AP. The V411M mutated model
produced a left shift of the curve half-maximal activation
(V1/2) of 8.1 mV (Figures 4B), a successful fit to the
reference 8.1 mV (Horne et al., 2011). The V411M model
produced a left shift on the V1/2 of 6.1 mV and a slope
increase of a 13.3%, consistent with the 7.9 mV and 13%
target values (Horne et al., 2011), respectively (Figures 4C).
Figures 4D depicts the reduction in inactivation time constants
at test potentials from −50 mV to 30 mV. Inactivation time
constants successfully diminished for the first portion of the
curve (voltages from −50 mV to −20 mV) showing good
agreement with the reference (Horne et al., 2011). Figures
4E,F show the simulated sodium current and the membrane
voltage time courses for both wild-type (black line) and
heterozygous mutation (red line) isolated endocardial cell
simulations, respectively. INaL increased from a maximum
value of 0.29 pA/pF in wild type to 0.75 pA/pF in the
repolarization phase of the action potential producing a
prolongation of the APD90 to 311.5 ms, or a 15.9% compared
to wild type (268.5 ms), despite a slight decrease in the early
plateau current. Therefore, our results show that the simulated




It is well known that flecainide produces an 8% prolongation of
the QT segment in healthy patients.2 However, between a 60 to a
90% of that prolongation can be caused by the beforementioned
QRS widening. Flecainide also blocks hERG channels (Paul et al.,
2002) and increases the conductance of the potassium rectifier
current IK1 (Caballero et al., 2010). To simulate the effects of
therapeutic concentrations of flecainide (1.5 µM), we applied a
27.7% reduction of hERG conductance (Paul et al., 2002), which
results from the Hill formalism with an IC50 of 3.91 µM and a Hill
coefficient of 1, and increased IK1 conductance by a 51%
according to published formula by Caballero et al. (2010).
We split the optimization of flecainide in three sequential
phases with increasing number of tests. First, since the drug has a
high pKa of 9.3 (Moreno et al., 2011), meaning it is 99% charged
at physiological pH conditions, we optimized the neutral form
parameters using two tests consisting of dose-dependent use-
dependent block and use-dependent block, while preventing the
2U.S. National Library of Medicine, Dailymed: https://dailymed.nlm.nih.gov/
dailymed/ [accessed 2019]
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remaining parameters from being modified during this step.
Later, we fixed the neutral form parameters before starting a
second phase optimization where charged flecainide variables
were allowed to evolve. This phase studied the steady state
availability, recovery from use-dependent block and the use-
dependence of the drug’s IC50 for the sodium current at three
frequencies of 0.2, 1 and 3 Hz, as in the work performed by
Penniman et al. (2010), who used the PatchXpress system. In
phase three, we ought to reproduce flecainide’s IC50 for INaL
obtained byMatsukawa et al. (2019) with the latest recommended
protocol by the Comprehensive In-vitro Proarrhythmia Assay
(CiPA) initiative. Furthermore, we also studied the APD90
prolongation produced by 1.5 µM flecainide on the isolated
endocardial cellular model, which we set to be as low as
possible (target was 0%). We allowed charged flecainide
affinities for the normal and bursting modes of the sodium
current to be modified during the optimization. Parameters
and equations of the final flecainide model are shown in
Table 4. We performed a sensitivity analysis of flecainide’s
parameters on the APD90 reduction of the isolated in-silico
V411M mutated endocardial cells. The results of this analysis
are included in the Supplementary Material (Supplementary
Figure S5B) together with the definition of the parameters
(Supplementary Table S3). Our study showed that the drug-
induced attenuation of the APD90 prolongation caused by
V411M was highly dependent on β4n and α4n (neutral
flecainide trapping dynamics, modulated by p13 and p14). The
affinity of charged flecainide for the bursting states also played a
relevant role (modulated by p16). Finally, there was also a smaller
yet noticeable dependence on an increase of β3+ and a decrease of
α3+ (inactivation and recovery from inactivation of the channels
bound to charged flecainide, modulated by p5 and p6).
Figures 5A–D compare targets (open squares) obtained from
experimental data and the simulated flecainide results (A: filled
circles, B-D: black lines), namely, use-dependent and recovery
from use-dependent block of neutral flecainide (Figures 5A,B),
steady-state availability and recovery from use-dependent block,
respectively. We included the wild type drug-free results in
Figures 5D for comparison (gray symbols). Figures 5E
compares the concentration-dependent availability of flecainide
(lines) to experimental data from Penniman et al. (2010) (open
squares) at 3, 1 and 0.2 Hz pacing rates (black, dark gray and light
gray, respectively). The corresponding half-maximal inhibitory
concentrations (IC50s) were 13, 4.73, and 3.59 µM, respectively.
Figures 5F shows the simulated effects of 1.5 µM flecainide
(green line) on the action potential of an isolated wild type
endocardial cell, which causes an APD90 prolongation of 1.2%
compared to drug-free conditions (black line). Details about the
construction these curves were described in the Supplementary
Material of this work. The simulated results obtained with our
new flecainide model are in very good agreement with the
experimental data. In addition, flecainide’s simulated IC50 INaL
was 1.65 µM (not shown), very close to reference experimental
data from Matsukawa et al. of 1.7 µM (Matsukawa et al., 2019).
Ranolazine
Ranolazine blocks hERG channels with an IC50 of approximately
35 µM (Moreno et al., 2013). In order to account for this effect, we
reduced the IKr conductance by a 22.3% when applying 10 µM
ranolazine, according to the Hill formalism (Hill coefficient of 1).
Ranolazine optimization was performed by assessing INaf and INaL
block dynamics, which were run in parallel in only one phase.
Parameters and equations of the final ranolazine model are
shown in Table 5. We performed a sensitivity analysis of
ranolazine’s parameters on the APD90 reduction of the
isolated in-silico V411M mutated endocardial cells. The results
of this analysis are included in the Supplementary Material
(Supplementary Figure S5C) together with the definition of the
parameters (Supplementary Table S4). The analysis revealed
that the drug-induced attenuation of the APD90 prolongation
caused by V411M was highly dependent on an increase of β3+
and a decrease of α3+ (inactivation and recovery from
inactivation of the channels bound to charged ranolazine,
modulated by p5 and p6), as well as a decrease of βx+ and an
increase of αx+ (recovery from slow inactivation and slow
inactivation of the channels bound to charged ranolazine,
modulated by p1 and p2). Although charged ranolazine’s
affinities (modulated by p11 and p12) were not optimized
TABLE 4 | Transition rates of the optimized flecainide model.
Names Equations
Transition rates
α11+ and α11n α11
α12+ and α12n α12
β11+ and β11n β11
















k_on  kc_on drug_charged×diffusion
k_off  kc_off 2.15e1×(1e-6)×exp((−0.7×V×F)/(R×T))×diffusion
kb_on  kcb_on k_on







Diffusion 5500 M−1 m−1
The first column indicates transition rate names while the second column indicates their
corresponding equations. The top section of the table defines drug transition rates, which
are analogous to their respective wild type counterparts. The bottom section of the table
defines drug-channel affinities. Nomenclature for transition rates and affinities: charged
drug (+), neutral drug (n), closed states (c), inactivated states (i), bursting states (b), drug
binding to the channel (on), drug unbinding from the channel (off).
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during the fitting process, they were included in this analysis to
make a comparison with flecainide results. They proved to be also
key for drug-induced APD90 shortening and their role was even
more relevant than in flecainide.
Figures 6A–E compares the results targets (open squares)
obtained from experimental data used by Moreno et al. (2013) to
the simulated ranolazine results (black lines), namely, steady-
state availability, tonic block of fast and late INa, use-dependent
block, recovery from use-dependent block and frequency-
dependent recovery from use-dependent block, respectively.
Protocols are described in Moreno et al. (2013) as well as the
Supplementary Material. IC50s for INaf and INaL were 153.4 µM
and 5.46 µM respectively, showing the specificity of the drug
toward the latter. Overall, our ranolazine model was in agreement
with the experimental data.
Effects of flecainide and ranolazine on the heterozygous
SCN5A V411M phenotype.
Once the drug-free sodium currents and the drug-channel
interactions were formulated, we proceeded to simulate the
effects of ranolazine and flecainide in the presence of the
V411M mutation on an isolated endocardial cell as well as on
a ventricular transmural wedge.
Figure 7 shows the effects of the application of therapeutic
concentrations of flecainide (green) and ranolazine (blue) in
isolated endocardial V411M mutated (red) cells, on the action
potential time courses (Figures 7A), time course of the late
component of the sodium current (Figures 7B), depolarization
phase of the AP (Figures 7C) and fast component of the sodium
current (Figures 7D). Therapeutic concentrations of ranolazine
and flecainide produced a shortening of the heterozygous mutant
APD90. Application of ranolazine resulted in a 298.1 ms APD90
(4.3% decrease) and exposure to flecainide resulted in a 284.5 ms
APD90 (8.7% decrease), although the mechanisms involved in
such results are different, as revealed by the corresponding INaL
time courses (Figures 7B). In fact, ranolazine reduced the
magnitude of the sodium current throughout the entire AP
time course. Peak INaL current, measured as the maximum
current during the repolarization, decreased from −0.75 pA/pF
to −0.52 pA/pF (orange arrows), while plateau currents,
measured at 100 ms from the start of the stimulus, decreased
from −0.16 pA/pF to −0.018 pA/pF (black arrows). By contrast,
flecainide had a major effect on INaL peak, whose value was much
smaller (from −0.75 pA/pF to −0.32 pA/pF) while the effects
during the plateau were less pronounced (from −0.16 pA/pF to
−0.080 pA/pF). The effect of both drugs on the total amount of
electronic charge carried by INaL, qNaL, which was calculated as
the integral of INaL was also quantified and they turned out to be
similar. Indeed, flecainide reduced qNaL from a value of
FIGURE 5 | Optimization of the flecainide model. Targets were represented as open squares (Liu et al., 2002; Liu et al., 2003; Penniman et al., 2010) and
simulations using our flecainide model as lines. (A,B) correspond to neutral flecainide, while the rest to neutral and charged flecainide. (A) Use-dependent block at 10 Hz
of neutral flecainide. (B)Recovery from use-dependent block of neutral flecainide. (C) Steady state availability. (D)Recovery from use-dependent block (black). Wild-type
drug free results (gray) were added for comparison. (E) Concentration-dependent availability at 3, 1 and 0.2 Hz (black, dark gray and light gray, respectively). (F)
Simulated wild type isolated endocardial action potential time course at therapeutic concentrations (1.5 µM, green) compared to drug-free (black). INaL IC50 was 1.65 µM
(not shown) and fitted to Matsukawa et al. (2019).
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−103.6 pC/pF in the mutant cells to −39.9 pC/pF and ranolazine
produced a similar reduction to −49.2 pC/pF, both values being
below the wild type value (−52.8 pC/pF). Figures 7C confirms the
differences in the block of the fast component of the sodium
current for both drugs. While ranolazine decreased the upstroke
velocity from 259.9 V/s to 213.3 V/s, flecainide produced a
stronger effect and reached 181.1 V/s as a consequence of its
affinity for the fast component of the current. This is linked with
the corresponding INaf time courses (Figures 7D). Ranolazine
reduced INa peak from −251.6 pA/pF to −204.8 pA/pF while
flecainide further reduced the peak to −172.6 pA/pF.
Therefore, our isolated cellular simulations suggest that
ranolazine could also be used to compensate the effects of the
heterozygous V411M mutation.
We further examined the effects of applying therapeutic
concentrations of flecainide and ranolazine in isolated
endocardial heterozygous V411M mutant cells at fast and slow
rates to see if the effects observed at 1 Hz hold at different
frequencies. Figure 8 shows the effects of flecainide (green)
and ranolazine (blue) on V411M mutated cells (red) at BCLs
600, 1,000, 1,500, and 2000 ms. This figure represents the APD90
(Figures 8A), the total amount of electronic charge carried by
INaL qNaL (Figures 8B), and the peak values of INaL and INaf
(Figures 8C,D). Our results show that both flecainide and
ranolazine reduce the APD90 prolongation induced by the
mutation for all the tested BCLs, flecainide’s APD90 reduction
being higher than ranolazine’s (Figures 8A). The effects of these
two drugs on qNaL aremore pronounced than on APD90 as qNaL
TABLE 5 | Transition rates of the optimized ranolazine model.
Name Values
Transition rates
α11+ and α11n α11
α12+ and α12n α12
β11+ and β11n β11












k_on  kc_on drug_charged×diffusion
k_off  kc_off 100.5×(1e-6)×exp((−0.7×V×F)/(R×T))×diffusion
kb_on  kcb_on k_on







Diffusion 5500 M−1 m−1
The first column indicates transition rate names while the second column indicates their
corresponding equations. See caption of Table 3 for definitions of the abbreviations.
FIGURE 6 |Optimization of the ranolazinemodel. Targetswere represented as
open squares and simulationswith our new ranolazinemodel as lines. (A)Steady state
availability of 10 µM ranolazine. (B) Tonic block of fast and late components of the
sodium current. (C) Use-dependent block. (D) Recovery from use-dependent
block of 10 µM ranolazine. (E) Frequency-dependent recovery from use-dependent
block of 100 µM ranolazine. Experimental data are from Moreno et al. (2013).
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in mutant cells in the presence of the drugs is similar and even
smaller than qNaL in WT cells (Figures 8B). The effects were
similar at all BCLs although slightly greater at fast pacing rates
(BCL 600 ms) compared to slow pacing rates (BCL 2000 ms). In
addition, both flecainide and ranolazine were able to reduce peak
INaL in the mutant phenotype at all pacing rates (Figures 8C).
However, flecainide-induced reduction was more acute, peak INaL
values being closer to the values in wild type. As a side effect, both
drugs exacerbated the reduction of peak INaf caused by V411M
mutation notably at fast rates, especially flecainide (Figures 8D).
In fact, while flecainide reduced peak INaf to −127.1 pA/pF from a
value of −242.9 pA/pF at a BCL of 600 ms, ranolazine reduced it
to −152.8 pA/pF. Our study suggests that the therapeutic effects
produced by ranolazine at 1 Hz in V411M mutated cells are
maintained at fast and slow rates, as in the case of flecainide.
Furthermore, ranolazine induced a smaller reduction of peak INaf
than flecainide at all pacing rates.
Considering the mechanisms that define drug effectiveness,
the sensitivity analyses we performed shed light into the key
parameters (see Supplementary Figure S5). Firstly, they revealed
that V411M mutation significantly increased INa activation and
accelerated recovery from inactivation. This could explain a
reactivation of the sodium current during repolarization due
to an increased availability of sodium channels for activation
earlier during the AP, which is supported by the fact that rates
that control the fraction of channels in bursting mode (µ1 and µ2)
were not altered. The main driver of flecainide’s effect on the
mutation consisted of the trapping dynamics of the channels
bound to neutral flecainide, but it also acted by binding to the
bursting states and slightly reducing recovery from inactivation of
the channels bound to charged flecainide (Supplementary Figure
S9). By contrast, ranolazine depended on an even combination of
decreased recovery from inactivation, increased slow inactivation
and bursting state binding of the channels bound to charged
ranolazine (Supplementary Figure S10). Ranolazine’s impact on
bursting state binding was nonetheless greater than flecainide’s.
In fact, when 10-fold ranolazine affinity reductions were
considered, no drug-induced APD90 shortening could be
observed, while in the case of flecainide it was 32% less
effective compared to baseline flecainide (see Supplementary
Figure S6). Likewise, ranolazine’s effect on the recovery from
inactivation was more important. A 10-fold increase in β3+
FIGURE 7 | Simulated effects of 10 µM ranolazine (blue) and 1.5 µM flecainide (green) in isolated endocardial heterozygous SCN5A V411M mutated (red) cells.
Drug-free wild-type (black) is also included for comparison. Action potential time courses (A), INaL time course (B), depolarization phase of the AP (C) and INaf time course
(D).
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doubled the reduction of the APD90 in ranolazine compared to an
increase of a 9.7% in flecainide. Therefore, while both drugs
shared a common affinity for the bursting states, their resulting
qNaL, peak INaL and APD90 reductions relied on different
mechanisms, indicating that flecainide took advantage of its
trapping dynamics while ranolazine relied on a combination of
factors including its high affinity for the bursting mode.
Next, we simulated the effects of ranolazine and flecainide on
the transmural wedge model. Figure 9 shows the simulated
effects of ranolazine (blue) and flecainide (green) on APs and
pseudo-ECGs in the presence of V411M heterozygous mutation
using a one-dimensional (1D) tissue model of a transmural wedge
preparation. This figure also includes the results in drug-free wild
type (black) conditions for comparison. Figures 9A–C represent
the APs of selected cells from the strand, specifically, #16, #80 and
#150. For the sake of clarity, we included a diagram of the
simulated strand. Figures 9D contains calculated pseudo-ECG
time courses with a virtual electrode 2 cm away from the last
epicardial cell. As shown in Figures 9A–C, APD decreased from
endocardial to epicardial cells for the simulated wild type drug
free transmural wedge preparation, as the progressive left shift of
the repolarization of the selected action potential time courses
indicates. APD90 values were 328.8, 310.7, and 279.6 ms for the
selected endocardial, midmyocardial and epicardial cells,
respectively. The simulated QT segment lasted 336.8 ms and
the QRS 18.4 ms. The APD90 prolongations produced by the
V411M heterozygous mutation were greater for endocardial cells,
followed by midmyocardial and epicardial cells, whose APD90
were 377.1, 350.7, and 314.5 ms respectively, corresponding to a
prolongation of 14.7, 12.9, and 12.5% compared toWT. The ECG
showed a prolongation of the QT segment of 48 ms (14.3%),
which is close to clinical observations (Horne et al., 2011;
Carrasco et al., 2012). Therapeutic concentrations of
ranolazine (10 µM) in the presence of the V411M
heterozygous mutation decreased the APDs of endocardial
(363.9 ms, −3.5%) and midmyocardial (343.8 ms, −2.0%) cells.
The calculated QT segment also decreased to 372.4 ms (−3.2%
compared to heterozygous mutation) in the presence of this drug.
Interestingly, the QRS values slightly increased (10.9%) as
expected from the small interaction of ranolazine with the fast
component of the sodium current. Flecainide therapeutic
concentrations (1.5 µM) caused a reduction of the APD90s in
all the selected cells. Specifically, endocardial, midmyocardial and
epicardial APD90s were 350.2 ms (−7.2%), 330.3 ms (−5.8%), and
303.5 ms (−3.5%), respectively. Flecainide reduced the QT
segment to 357.1 ms (−7.2%). The effects of the drug on INaf
were stronger than ranolazine’s, as expected, widening the QRS
complex by a 23.4%. Interestingly, the results obtained using the
isolated endocardial model translated very well to the strand
model. Specifically, both drugs reduced the QT segment duration
by a similar extent, although flecainide was slightly more effective,
and widened the QRS more than ranolazine, which is related to
the corresponding reductions in upstroke velocity. Therefore, our
transmural wedge simulations reinforce that ranolazine could
also be used to compensate the effects of the V411M heterozygous
mutation.
As arrhythmias associated to LQT3 typically manifest at
bradycardic rates, we investigated the potential of ranolazine
to mitigate abnormal electrophysiological phenotypes arising
from the V411M mutation at slow pacing rates. Figure 10
illustrates the simulated steady-state time courses of
membrane potential (A) and INa (B) of an isolated
midmyocardial heterozygous V411M mutant cell paced at a
BCL of 3,000 ms in the absence of any drug (red) and in the
presence of therapeutic concentrations of flecainide (green) and
ranolazine (blue). Wild type time courses (black) were also
included for comparison. The mutation increased INaL during
the late plateau (red trace), which led to EADs (black arrow).
Therapeutic concentrations of both flecainide and ranolazine
reduced INaL and successfully normalized AP morphology and
avoided EAD generation. These results suggest that ranolazine
could also prevent the development of potentially arrhythmia-
triggering EADs at slow pacing rates in patients with
heterozygous V411M, similarly to flecainide.
FIGURE 8 | Simulated effects of 10 µM ranolazine (blue) and 1.5 µM
flecainide (green) on the restitution dynamics of the APD90 (A), qNaL (B) and
peak INaL (C) in isolated endocardial heterozygous SCN5A V411M mutated
(red) cells. Drug-free wild type (black) is also included for comparison.
qNaL, the total amount of electronic charge carried by INaL, was calculated as
the area under the curve of INaL.
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DISCUSSION
Main Findings
In this work, we aimed to study the potential use of ranolazine as a
treatment for patients with LQT3 caused by the heterozygous
V411M mutation, and to compare its effects to those produced
by flecainide, using computational simulations. For this purpose,
first, we optimized existing Markovian models of the wild type
cardiac sodium current in the absence of drugs and under exposure
to flecainide and ranolazine, which are two sodium current-
blocking antiarrhythmic drugs. The proposed wild type model
improves the INaL time course, the current-voltage relationship
and the endocardial APD90 restitution curve. The models of
ranolazine and flecainide were adapted to the new wild type,
and in the case of flecainide, to reproduce new experimental and
clinical data. Indeed, flecainide optimization was constrained with
new tests assessing its INaL blocking potency using the latest
recommended patch-clamp protocol, and the prolongation of
the APD90 of the endocardial cellular model under exposure to
therapeutic concentrations. Then, we generated a formulation of the
gain-of-function V411M mutation to reproduce voltage clamp
recordings and the QT prolongation clinically observed.
Simulation of the electrophysiological activity in the presence of
this mutation showed an increase of INaL during late repolarization.
Additionally, we tested the effectiveness of both drugs as treatments
for the mutation in an isolated cellular and a transmural wedge
model and we found that they were both capable of countering
APD90 and QT prolongations, although the subjacent
FIGURE 9 | Simulated effects of 10 µM ranolazine (blue) and 1.5 µM flecainide (green) on action potentials and pseudo-ECGs in the presence of SCN5A V411M
heterozygousmutation (red) using a one-dimensional (1D) tissuemodel of a transmural wedge preparation. Drug-free wild type (black) was also included for comparison.
Action potentials from endocardial (A), midmyocardial (B) and epicardial cells (C). Representation of the simulated transmural 1D tissue, and its corresponding pseudo-
ECG (D) obtained with a virtual electrode 2 cm away from the last epicardial cell.
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electrophysiological mechanism differed. Indeed, while ranolazine
reduced INaL throughout the action potential, flecainide was more
specific of the late repolarization peak at a wide range of pacing
rates. Additionally, EADs triggered during slow pacing were
prevented by therapeutic concentrations of flecainide and
ranolazine alike.
Therefore, our study suggests that ranolazine could be applied
in patients with LQT3 caused by the heterozygous V411M
mutation that could not be treated with flecainide.
Ranolazine and Flecainide for LQT3
Patients
Several authors have shown that ranolazine could reverse abnormalities
found in patients with LQTS type 3 characterized by an abnormal
increase in INaL (Kaufman, 2008; Moss et al., 2008; Chorin et al., 2016),
which is in accordance with our results. Moreno et al. (2013) simulated
the effects of ranolazine in the presence of the SCN5A ΔKPQmutation
associated to a severe overlapping phenotype including LQTS type 3,
Brugada syndrome and conduction disease (Moss et al., 2005).Moreno
and coworkers concluded that a reduction of INaL with ranolazine
might be an effective therapeutic strategy. Indeed, this mutation
induced an increase in INaL that causes a LQTS type 3 where
patients frequently suffered from tachyarrhythmias. The authors
found that ranolazine was able to stabilize the mutation induced
EADs by considerably reducing INaL in three human cardiomyocyte
isolated cell action potential models, reporting a 50% or higher
reduction of the APD90 at 10 µM ranolazine. In our work,
ranolazine reduced by a 4.3% the APD90 in isolated endocardial
cells with the SCN5A V411M mutation. The lesser extent of the
reduction observed in our simulations compared to that of Moreno
et al. (2013) can be due to the fact that ranolazine binds with high
affinity to bursting channels, whose proportion is much higher in the
ΔKPQ mutation than in the V411M mutation. Specifically, the ΔKPQ
mutation provoked up to a five-fold increase of the persistent INaL by
drastically increasing the proportion of channels in bursting mode
(Moreno et al., 2013), opposite to the V411Mmutation. Therefore, our
simulation results reveal that ranolazine could be useful in the
treatment of patients with the SCN5A V411M mutation, although
its beneficial effects may not be as dramatic as in the case of the ΔKPQ
mutation.
Regarding flecainide, it was able to almost completely
compensate the mutation phenotype in combination with
β-blocker (propranolol) in two case-reports (Carrasco et al.,
2012; Blich et al., 2019). In our work, flecainide reduced the
QT interval of the isolated endocardial cell to a point comprised
between the wild type values and those corresponding to the
mutated cells, suggesting a smaller effect that in the clinical
practice. Possible reasons for the discrepancy in the APD
reductions could consist of in-silico and in vitro differences,
the drug IKr or INaL real blocking potency or in other ionic
current densities that obviously interact in the human model and
are obviated in the transfected cell models. The real blocking
effect of flecainide on INaL remains elusive. Although we used
updated IC50 data, we acknowledge that IC50 values reported in
the literature widely range from 3.4 µM (Belardinelli et al., 2013)
to 44 µM (Nagatomo et al., 2000), with medium potencies
observed such as 19 µM (Crumb et al., 2016). More recent
studies aimed at determining INaL IC50 using a novel protocol
for high throughput ion channel screening showed much lower
values, such as 1.7 µM (Matsukawa et al., 2019) or 1.9 µM (Guo
and Jenkinson, 2019). These protocols give more accurate values
of the INaL blocking power of the drug during the action
potential since they measure the current elicited by a
decreasing ramp after a pulse that is intended to mimic the
repolarization phase of the action potential, contrary to previous
studies that measure the remaining INaL current at a fixed interval
after application of a voltage step (Guo and Jenkinson, 2019). Our
optimized flecainide model used these new protocols and data,
representing an improvement over the original Moreno et al.
(2013) model (Moreno et al., 2013). Finally, even though
flecainide may produce a small QTc prolongation (8%3) in
FIGURE 10 | Simulated effects of 10 µM ranolazine (blue) and 1.5 µM flecainide (green) on EAD generation in slow paced (BCL  3,000 ms) isolated midmyocardial
heterozygous SCN5A V411M mutated (red) cells. Drug-free wild type (black) is also included for comparison.
3U.S. National Library of Medicine, Dailymed: https://dailymed.nlm.nih.gov/
dailymed/ [accessed 2019]
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clinical practice QRS widening was the main contributor
(60–90%3), an effect that is related to INaf block. These
clinical observations are in keeping with the absence of
APD90 prolongation in ventricular cells (Smallwood et al.,
1989; Lu et al., 2008), which we took into consideration in
our fittings. Despite the INaL IC50 test showing good results in
our work, flecainide incompletely counteracted the APD90
prolongation produced by the presence of the heterozygous
mutation. A possible reason could be that we had
overestimated the IKr blocking effect of flecainide due to in
vitro-in vivo differences in terms either of drug exposure or the
values of the ionic current conductances in the action potential
model, whose experimental measurement is subject to a high
variability. Indeed, a smaller contribution of IKr to the action
potential time course would result in a smaller impact on the
repolarization reserve of the cell and a subsequent shorter
APD90 prolongation, thus helping close the gap between
clinical observations and the simulations with flecainide in
the presence of the mutation. To assess the impact of blocking
IKr on APD90 prolongation we simulated the effects that
therapeutic concentrations of flecainide and ranolazine
would have on isolated heterozygous mutant cells without
considering the effects on IKr and IK1. Our results show that
both drugs would reduce the APD90s of the mutant cells close
to, and even below, the WT value (Supplementary Figure S6).
In conclusion, our simulation results show that ranolazine
induces a similar qNaL reduction to flecainide, bringing it close
to wild type values, and reduces QT/APD90 prolongation
caused by V411M mutation, although to a lesser extent than
flecainide. Like flecainide, ranolazine was also able to prevent
arrhythmia triggers, suggesting that it could be useful in
treating LQTS type 3 patients carrying V411M mutation.
Unlike flecainide, ranolazine would also be safe in the
presence of structural heart disease (Andrikopoulos, 2015)
and the scarcity of evidence also supports its use in patients
with overlap phenotype manifesting with Brugada syndrome or
conduction disease in addition to the LQTS type 3 phenotype,
although such a behavior has never been reported for V411M
carriers.
Ionic Models
The crucial role of INaL in cardiac electrophysiology puts into
perspective some relevant contributions of this work, namely,
the improvement of the formulation of the sodium current and
the updates of the flecainide and ranolazine models. In the
present work, we improved INaL by increasing its contribution to
the APD restitution and optimizing its time course. This
resulted in a reduction of the late peak (compared to Moreno
et al., 2013) and an increment over the whole action potential.
According to Horne et al. (2011), the V411M mutation induced
an increment of the sodium current during repolarization. They
suggested that the cause was an increase in window current due
to reactivation of the channels. Our work is in agreement with
the authors as our simulations reproduce the shifts of the
activation and inactivation steady state curves, resulting in a
greater window current that occurs during repolarization.
Horne et al. (2011) suggested that the specific open state
blocker flecainide would be useful in treating the condition,
which was later confirmed by Carrasco et al. (2012). Our work
provided a mechanistic insight into why flecainide is a good
treatment by showing its specific effect on the V411M mutation
induced INaL peak and tested ranolazine as a possible alternative
treatment.
Limitations
Our optimizations were designed using the Nelder-Mead
algorithm, as in other studies (Moreno et al., 2011; Moreno
et al., 2013; Moreno et al., 2016; Romero et al., 2015; Yang et al.,
2016b). This algorithm benefits from being simple to implement,
parallelizable and requiring “less” computational power than
other optimization algorithms. However, some notable
limitations include its high likelihood of finding a local
instead of a global minimum and its slowness, requiring a
higher number of iterations (Moreno et al., 2016). As our
goal was to refit the existing models by adding a few new
tests, we limited the number of iterations to 300, which
reduced the computational cost of our optimizations. In order
to reduce the likelihood of finding a local minimum we
randomized 10 sets of initial parameters with a 10%
variability instead of creating radically different sets of
parameters, as the initial parameters already yielded close
results to many of the tests.
Simulations of the APD90 restitution curve in wild type, the
prolongation of the APD90 for V411M mutated cells and the
effects of flecainide on APD90 for each iteration were not
obtained by applying a train of pulses until reaching the
steady state, as it would have resulted in a very high
computational demand. As explained in Methods, we first
paced the drug-free wild type model for 300 s at 1 Hz pacing
rate for each case and the final states were saved. They were
used as initial states in the optimization procedure and a train
of 40 pulses was applied to the isolated endocardial cell models
for each iteration. Additionally, we brought the isolated
endocardial, midmyocardial and epicardial models to steady
state with 300 pulses at 1 Hz pacing rate to prepare for tissue
simulations.
Horne et al. analyzed the V411M mutated sodium channels
with a patch-clamp protocol including a voltage ramp which
they used to assess INaL current density Horne et al. (2011),
(Figure 5). The increase in INaL that was required to reproduce
clinical QT prolongations in our model was greater than the
one registered by Horne et al. in-vitro. Therefore, we did not
include this protocol in our optimization procedure. A possible
explanation to this discrepancy could be that the current
density changes that the mutation produces in the
transfected HEK293 cells may differ from those in human
cardiomyocytes. In the heart, Nav1.5 is associated not only
with several accessory proteins that modulate its trafficking and
biophysical properties, but also with other structural and
signaling complexes in the cardiomyocyte, such as caveolin
and syntrophin (Bohnen et al., 2017). Nevertheless, as new
works make their way to the literature, their data could be
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integrated to this model to improve it further favored by its
inherited versatility.
A recent work by Horváth et al. (2020) compared human,
guinea pig and dog INaL time courses using the same protocols.
They found that dog and human INaL showed a similar
“decrescendo” behavior, contrary to guinea pig INaL whose
time course followed a “crescendo” pattern in addition to
having slower inactivation dynamics. They concluded that
dog cardiomyocytes were more suitable for INaL
pharmacological studies. Although we used a guinea pig
time course in the fitting of our wild-type model (Horvath
et al., 2013), we still improved the formulation proposed by
Moreno et al., 2013 as we reduced the contribution of the
current to the late repolarization phase. Our improved model
shows now a flatter time course similar to the one in the ORd
modified by Dutta and coworkers (Dutta et al., 2017) at 1 and
2 Hz.
Since we did not account for β-stimulation in our models, we
used the QTc values of our patients while being treated with
β-blocking drugs to model the effects of the V411M mutation.
However, the reference values were obtained from subjects
lacking such treatment.
A recent work by Zhu et al. (2019) found that sodium channel
block by mexiletine differed between LQTS type 3 induced
mutations. In this work, the same values of drug affinities
were used for wild type and V411M mutated cells, although
they could be altered by the mutation (Ficker et al., 1998). In
order to take into account a possible difference in drug affinities
between wild type and V411M mutated cells additional
experimental data would be needed.
Our study would also benefit from the simulation of flecainide
and ranolazine using a population of models that account for
natural variability among individuals of the same species (Sobie,
2009; Britton et al., 2013). This would help to better predict the
effectiveness in population of patients.
Finally, it should be noted that our results might be model
or parameter dependent, although qualitatively they should
hold. The models used in our work were the result of fitting the
parameters of the original Moreno and coworkers Markov
formulation of INa to reproduce experimental results from the
literature using a specific action potential model. This was the
Grandi et al. (2010) with Soltis and Saucerman (2010) model,
which has already been used in similar conditions than our
work (Moreno et al., 2013). Inserting our INa formulation in a
different action potential model would require refitting of the
parameters to reproduce experimental data. Likewise, the
parameters we obtained result from the particular dataset
we used to fit them, which covered a wide range of INa
dynamics in all optimizations. Therefore, the assessment of
ranolazine’s and flecainide’s impact on the V411M mutation
phenotype using different action potential models or datasets
might be quantitatively different, but qualitatively similar, as
the models should capture the mechanisms of both mutation
and drugs.
All in all, we believe that these limitations do not jeopardize
the main conclusions of this work.
CONCLUSION
In this work, we improved an existing Markovian wild type cardiac
sodium channel model with new INaL experimental data. Then, we
fitted a new model for the gain-of-function V411M mutation. We
also updated two antiarrhythmic drug models—flecainide and
ranolazine—that we used to test their efficacy as treatments for
the V411M phenotype. We found that both drugs could be
beneficial because of their APD90 and QT shortening effect at a
wide range of pacing rates. Both reduced the total charge carried by
INaL close to wild type values, but flecainide was more effective at
reducing the mutation induced late sodium current peak.
Ranolazine reduced peak INaf to a lesser extent than flecainide,
which would be beneficial for some patients. Importantly, our
simulations suggest that, similarly to flecainide, ranolazine has the
potential to prevent arrhythmia triggers during bradycardia
episodes in patients with V411M mutation.
Our study is the first to model the V411M mutation in great
detail, providing a deeper understanding of the underlying
mechanisms of the mutation phenotype. We also provided
insights into the mechanisms that drive the effectiveness of
two antiarrhythmic drugs, flecainide and ranolazine. Our
results support the fact that, while flecainide was better suited
to counter the mutation, ranolazine could be beneficial via a
different mechanism. Therefore, our computational study
suggests that patients with LQTS 3 caused by the heterozygous
V411M mutation could be treated with ranolazine. Finally, our
work provides new tools to further explore new treatments for the
V411M or other similar mutations.
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